Literature DB >> 6315259

Comparative effects of propranolol and verapamil alone and in combination on left ventricular function and volumes in patients with chronic exertional angina: a double-blind, placebo-controlled, randomized, crossover study with radionuclide ventriculography.

D L Johnston, V A Gebhardt, A Donald, W J Kostuk.   

Abstract

With the use of equilibrium radionuclide ventriculography the effects on left ventricular (LV) function of 160 mg oral propranolol daily and 360 mg verapamil daily alone and in combination were compared in 18 patients with chronic exertional angina. A randomized, double-blind, placebo-controlled, crossover protocol was used. The reduction in exercise rate-pressure product induced by the combination (118 +/- 28 mm Hg/min) was significantly greater (p less than .05) than that by propranolol (135 +/- 27 mm Hg/min) or verapamil alone (163 +/- 28 mm Hg/min). In patients at rest, neither single nor combined therapy altered global or regional left ventricular ejection fractions (EFs). Verapamil, but not propranolol, increased (p less than .05) cardiac volumes of resting subjects; used in combination, no further increase in LV volume occurred. With placebo, exercise global EF did not decrease from the level at rest and therefore no drug effect could be demonstrated for this parameter of LV function. By an evaluation of normalized regional EF measurements the combination was shown to reduce exercise-induced hypokinesis (placebo 52 +/- 20%, combination 61 +/- 23%; p less than .01). No significant improvement was noted with propranolol or verapamil alone; only the combination prevented a significant increase in end-systolic and end-diastolic volumes during exercise. Thus, propranolol and verapamil, used alone in moderate doses, exert no beneficial effect on exercise LV function as measured by EF and volume changes, and resting function deteriorates slightly with verapamil.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315259     DOI: 10.1161/01.cir.68.6.1280

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

2.  Treatment of angina pectoris with nifedipine and atenolol: efficacy and effect on cardiac function.

Authors:  I N Findlay; K MacLeod; M Ford; G Gillen; A T Elliott; H J Dargie
Journal:  Br Heart J       Date:  1986-03

3.  Beta blockers and verapamil: a cautionary tale.

Authors:  I N Findlay; G T McInnes; H J Dargie
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-20

Review 4.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 5.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

6.  A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris.

Authors:  I N Findlay; K MacLeod; G Gillen; A T Elliott; T Aitchison; H J Dargie
Journal:  Br Heart J       Date:  1987-04

7.  Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction.

Authors:  S H Sial; M Malone; J L Freeman; R Battiola; J Nachodsky; J S Goodwin
Journal:  J Gen Intern Med       Date:  1994-11       Impact factor: 5.128

8.  Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina.

Authors:  T E Meyer; C Adnams; P Commerford
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

Review 9.  The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.

Authors:  A L Soward; G L Vanhaleweyk; P W Serruys
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

10.  The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention.

Authors:  Jiesuck Park; Jung-Kyu Han; Jeehoon Kang; In-Ho Chae; Sung Yun Lee; Young Jin Choi; Jay Young Rhew; Seung-Woon Rha; Eun-Seok Shin; Seong-Ill Woo; Han Cheol Lee; Kook-Jin Chun; DooIl Kim; Jin-Ok Jeong; Jang-Whan Bae; Han-Mo Yang; Kyung Woo Park; Hyun-Jae Kang; Bon-Kwon Koo; Hyo-Soo Kim
Journal:  Korean Circ J       Date:  2022-04-04       Impact factor: 3.101

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.